Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag in sarcoidosis-associated pulmonary hypertension (SAPH)
2018-004887-74Phase 2Unknown
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sarcoidosis-associated pulmonary hypertension (SAPH) and pulmonary hypertension (PH) comparing Selexipag with Placebo (2 arms). Primary endpoint: Pulmonary vascular resistance at Week 26 (percent change from baseline). Status: unknown.
02
Drugs
selexipag
03
Conditions
Sarcoidosis-associated pulmonary hypertension (SAPH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2018-004887-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004887-74.